Welcome to our dedicated page for QUANTUM GENOMICS ORD news (Ticker: QNNTF), a resource for investors and traders seeking the latest updates and insights on QUANTUM GENOMICS ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QUANTUM GENOMICS ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QUANTUM GENOMICS ORD's position in the market.
Quantum Genomics has published a new article in the Canadian Journal of Cardiology detailing the efficacy of its drug candidate, QGC606, for treating heart failure following myocardial infarction. The study, conducted with INSERM, shows that QGC606 improves cardiac function at a dose six times lower than firibastat and is comparable to ramipril without affecting blood pressure. This positions QGC606 as a potential best-in-class product, reinforcing the company's innovative approach in treating resistant hypertension and heart failure.
Quantum Genomics, a biopharmaceutical company listed as QNNTF, announced the granting of new patents for its drug candidate QGC606, aimed at treating resistant hypertension and heart failure. The US Patent and Trademark Office and Australian Patent Office have validated the patents which protect the drug until March 2040. This development reinforces the company's intellectual property and confidence in its innovative approach to cardiovascular treatment, as stated by company executives.
Quantum Genomics announced the appointment of Stéphane Cohen as Director of Global Operations to enhance international partnerships and operational strategy ahead of the market launch of firibastat. Cohen brings over 18 years of experience, having previously held senior roles at Bayer and Pfizer, and is expected to leverage his expertise in specialty care products to support the company's growth. Quantum Genomics, focused on treating resistant hypertension and heart failure through its innovative Brain Aminopeptidase A Inhibition (BAPAI) approach, has secured seven partnership agreements to date.
Quantum Genomics has announced a partnership with Julphar, which will receive exclusive rights to manufacture and market firibastat in the MENA region, all African countries, CIS, and Turkey. Quantum Genomics will gain up to $20 million in upfront and milestone payments along with royalties on future sales. Julphar will also invest $2 million in Quantum Genomics. This collaboration aims to address hypertension treatments in these regions, leveraging Julphar's advanced production facilities.
Quantum Genomics has signed an exclusive licensing agreement with Teva Israel Ltd. for the marketing of firibastat in Israel, targeting resistant hypertension.
The biopharmaceutical company will receive up to $11 million and a minimum of 25%, possibly up to 30%, in royalties from future sales.
Teva, a leading global pharmaceutical firm, will manage the marketing and distribution, expanding firibastat's reach in treating cardiovascular diseases. This partnership aims to fulfill a significant unmet medical need in Israel.
Quantum Genomics has announced the approval of the phase III REFRESH study in South Korea and Taiwan, aimed at treating resistant hypertension with firibastat. This pivotal study, supported by partnerships with DongWha and OEP, is expected to recruit 750 patients across 106 centers in several countries. The first patients are set to be recruited soon, and milestone payments are anticipated by year-end. The company aims for firibastat to be market-ready by late 2023, aligning with ongoing pre-marketing activities to enhance its market presence.
Quantum Genomics has announced promising results from the Phase IIb QUORUM study for firibastat, demonstrating its efficacy comparable to ramipril in preventing left ventricular ejection fraction degradation after myocardial infarction. Firibastat showed superior efficacy in severe patients with low ejection fractions and improved blood pressure profiles. The drug also exhibited a favorable safety profile, with minimal side effects. These findings pave the way for a potential Phase III study, emphasizing firibastat's role as a significant advancement in cardiovascular treatment.
Quantum Genomics has commenced the REFRESH study, enrolling its first patient for a pivotal phase III trial of firibastat, targeting treatment-resistant hypertension. This multicenter study will involve 750 patients across 96 sites in various countries including the US and South Korea. The trial aims to assess the medication's effectiveness and safety over several months, with results expected by mid-2023. The company is preparing for a New Drug Application by Q4 2023, aligning with FDA standards for this innovative treatment.
Quantum Genomics, a biopharmaceutical firm listed as QNNTF, announced it will present preclinical study results of its drug QGC606 for heart failure at the European Society of Cardiology annual congress on August 28, 2021. The study, which examines QGC606's effects on cardiac function after myocardial infarction, was conducted in collaboration with INSERM. This innovative prodrug targets resistant hypertension and heart failure, a condition that affects many patients. Quantum Genomics aims to develop breakthrough treatments based on over 20 years of research.
Quantum Genomics announces a groundbreaking publication in Biomedicine & Pharmacotherapy detailing the efficacy of firibastat in treating salt-sensitive hypertension. The study compares the effects of firibastat in combination with enalapril and hydrochlorothiazide versus other treatments and highlights a significantly greater hypotensive effect. The research supports Quantum's strategy to enhance blood pressure control in challenging cases. This is part of their ongoing Phase III clinical studies, emphasizing their innovative approach targeting the brain's mechanisms.
FAQ
What is the market cap of QUANTUM GENOMICS ORD (QNNTF)?
